Vaginal cancer
Drug research and approvals for vaginal cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 65 studies of vaginal cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 65
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological CancersNCT07902375 · Not applicable · Universiteit Antwerpen · starts Jun 19, 2026
- Predictors of Success and Failure of v-NOTES Hysterectomy for Large and Very Large UteriNCT07895953 · Not reported · University Hospital, Strasbourg, France · starts Mar 20, 2026
- Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic LesionsNCT07883798 · Not reported · Affidea Nu-med Center of Oncological DIagnostics and Therapy · starts Oct 6, 2026
- Vagina-View Safety and Imaging FeasibilityNCT07818850 · Not applicable · University Health Network, Toronto · starts Sep 15, 2026
- A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast CancerNCT07741968 · Not applicable · City of Hope Medical Center · starts Sep 9, 2026
- Deep Neuromuscular Blockade and a Low-Residue Diet for the Surgical Field in vNOTES HysterectomyNCT07730970 · Not applicable · Fatih Sultan Mehmet Training and Research Hospital · starts Jul 1, 2026
- Reirradiation and Total Ablative Strategies for Recurrent Gynecologic CancerNCT07667192 · Not reported · Affidea Nu-med Center of Oncological DIagnostics and Therapy · starts Jun 11, 2026
- Vaginal Fluid Derived Biomarkers in the Early Detection and Evolution of Gynaecological CancersNCT07622953 · Not reported · University Hospital Southampton NHS Foundation Trust · starts Jan 14, 2026
- Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial CancerNCT07527143 · Not reported · Mayo Clinic · starts Jun 10, 2026
Phase 1 or earlier 10
- CarboplatinDNA inhibitor
- DocetaxelTubulin inhibitor
- PaclitaxelTubulin inhibitor
- TrastuzumabReceptor protein-tyrosine kinase erbB-2 inhibitor
- VinorelbineTubulin inhibitor
- EntinostatHistone deacetylase inhibitor
- Bintrafusp alfaProgrammed cell death 1 ligand 1 binding agent
- Edodekin alfa
- Immunocytokine NHS-IL12
- Pexipepimut-s
How its trials ended
121 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 23 whose ending is known, 39% met their primary endpoint, 9% missed it and 52% stopped early.
- Completed, result not reported5041%
- Ongoing4033%
- Met its primary endpoint97%
- Status unknown87%
- Stopped: enrollment or feasibility65%
- Stopped: other or unclear65%
- Missed its primary endpoint22%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA